Fig. 2: Best overall response and Kaplan–Meier estimates of investigator-assessed response outcomes. | Nature Cancer

Fig. 2: Best overall response and Kaplan–Meier estimates of investigator-assessed response outcomes.

From: Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial

Fig. 2

a, Best overall response in the mITT population (all participants treated with axi-cel and ≥1 cycle of rituximab after axi-cel treatment, n = 26). Numbers in brackets reflect the proportion of patients with the indicated response. Objective responses were assessed by the investigator per Lugano classification38. b, Kaplan–Meier estimates of DOR, PFS and OS for the mITT population.

Source data

Back to article page